Article
Medicine, General & Internal
Pattamaporn Boonlerd, Adisak Tantiworawit, Lalita Norasetthada, Chatree Chai-Adisaksopha, Teerachat Punnachet, Nonthakorn Hantrakun, Pokpong Piriyakhuntorn, Thanawat Rattanathammethee, Sasinee Hantrakool, Ekarat Rattarittamrong
Summary: The efficacy of salvage chemotherapy using ESHAP and DICE regimens for relapsed or refractory DLBCL showed no significant difference in terms of two-year PFS, two-year OS, and ORR. The DICE regimen exhibited fewer renal adverse events compared to ESHAP.
ANNALS OF MEDICINE
(2023)
Article
Immunology
Xianggui Yuan, Xian Li, Yurong Huang, Xueli Jin, Hui Liu, Aiqi Zhao, Weiping Zhang, Wenbin Qian, Yun Liang
Summary: This study evaluated the efficacy and safety of zanubrutinib plus salvage chemotherapy in R/R DLBCL patients and found that it showed high efficacy and manageable tolerability. Additionally, CAR-T cell therapy may be a priority strategy for poor responders to BTKi-based treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Lucia Pedrosa, Ismael Fernandez-Miranda, David Perez-Callejo, Cristina Quero, Marta Rodriguez, Paloma Martin-Acosta, Sagrario Gomez, Julia Gonzalez-Rincon, Adrian Santos, Carlos Tarin, Juan F. Garcia, Francisco R. Garcia-Arroyo, Antonio Rueda, Francisca I. Camacho, Monica Garcia-Cosio, Ana Heredero, Marta Llanos, Manuela Mollejo, Miguel Piris-Villaespesa, Jose Gomez-Codina, Natalia Yanguas-Casas, Antonio Sanchez, Miguel A. Piris, Mariano Provencio, Margarita Sanchez-Beato
Summary: This study investigated the genetic subtypes of diffuse large B-cell lymphoma, identified mutated genes associated with treatment outcomes and survival, and proposed a two-step genetic DLBCL classifier. Different genetic subtypes have different impacts on patients' prognosis, with patients in the ST2(2-S) group having the best clinical outcome.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Yao Wang, Chuan Tong, Yuting Lu, Zhiqiang Wu, Yelei Guo, Yang Liu, Jianshu Wei, Chunmeng Wang, Qingming Yang, Weidong Han
Summary: CAR-T cell therapy has become an important treatment option for patients with relapsed/refractory B-cell malignancies, but a significant number of DLBCL patients fail to achieve durable response. This study analyzed the characteristics of pre-manufacture T cells and CAR-T cell products in DLBCL patients and identified the key role of CD8+ stem cell-like memory T cells in achieving durable clinical response. Heterogeneity in the cellular and molecular features of pre-manufacture T cells contributes to the variation in efficacy after CAR-T cell therapy, and loss of CCR7 gene expression and increased expression of activation- and inhibitor-related genes in CD8+ naive-T cell populations may explain the differences in anti-tumor efficacy among patients with different clinical outcomes.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Oncology
Lan-Hsi Lin, Mohammad Ghasemi, Sarah M. Burke, Cory K. Mavis, Jenna R. Nichols, Pallawi Torka, Donald E. Mager, Francisco J. Hernandez-Ilizaliturri, Andrew K. L. Goey
Summary: A population-based pharmacokinetic/pharmacodynamic (PK/PD) model of carfilzomib was successfully developed through a clinical trial. The model can be used to study the drug metabolism and effects in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who receive carfilzomib in combination with R-ICE regimen. The study results show that the model estimates are accurate, but further research is needed to identify sources of variability in response to carfilzomib treatment in combination with R-ICE.
Review
Hematology
Eliza A. Hawkes, Allison Barraclough, Laurie H. Sehn
Summary: Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype, has a good prognosis in limited-stage DLBCL (LS-DLBCL) patients. Recent studies have provided new insights and strategies for the treatment of LS-DLBCL, including the use of PET scans and clinical trials. However, there is currently no standard definition for LS-DLBCL, and treatment strategies vary across studies, posing challenges in interpretation.
Article
Oncology
Danielle N. Blunt, Liam Smyth, Chenthila Nagamuthu, Evgenia Gatov, Ruth Croxford, Lee Mozessohn, Matthew C. Cheung
Summary: A study in Ontario, Canada found that in patients with diffuse large B-cell lymphoma (DLBCL), the length of time from diagnosis to treatment initiation (DTI) was associated with overall survival (OS), with shorter DTI indicating poorer survival. Increasing age, male sex, and the number of comorbidities were also linked to inferior survival outcomes. This suggests that DTI may serve as a surrogate marker for aggressive biology and that clinical trials with lengthy screening periods could create biases in patient selection.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Medicine, General & Internal
Herve Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, M. Trneny, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Shinya Rai, Koji Izutsu, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Richard Greil, Larysa Mykhalska, Juan M. Bergua-Burgues, Matthew C. Cheung, Antonio Pinto, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta, Jyh-Pyng Gau, Jamie Hirata, Yanwen Jiang, Mark Yan, Calvin Lee, Christopher R. Flowers, Gilles Salles
Summary: In untreated intermediate-risk or high-risk DLBCL patients, those who received pola-R-CHP had a lower risk of disease progression, relapse, or death compared to those who received R-CHOP. Overall survival and safety profiles were similar between the two groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, David W. Scott, Qingyuan Zhang, Wojciech Jurczak, Muhit Ozcan, Xiaonan Hong, Jun Zhu, Jie Jin, David Belada, Juan Miguel Bergua, Francesco Piazza, Heidi Mocikova, Anna Lia Molinari, Dok Hyun Yoon, Federica Cavallo, Monica Tani, Kazuhito Yamamoto, Koji Izutsu, Koji Kato, Myron Czuczman, Sarah Hersey, Adrian Kilcoyne, Jacqueline Russo, Krista Hudak, Jingshan Zhang, Steve Wade, Thomas E. Witzig, Umberto Vitolo
Summary: The ROBUST study aimed to compare the efficacy of lenalidomide plus R-CHOP with placebo/R-CHOP in previously untreated ABC-type DLBCL. While the primary end point of progression-free survival (PFS) was not met in all patients, there were trends favoring R2-CHOP over placebo/R-CHOP in patients with higher-risk disease. The safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Thomas M. Habermann
Summary: Several important updates have emerged in the management of early-stage diffuse large B-cell lymphoma, including the approval of the R-CHOP regimen for international use and studies on the optimal number of treatment cycles without radiation therapy. Tailored treatment strategies are recommended for patients with extranodal diseases, with molecular subtype evaluations potentially changing treatment approaches.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Review
Oncology
Annalisa Arcari, Federica Cavallo, Benedetta Puccini, Daniele Vallisa
Summary: Most patients with Diffuse Large B-cell Lymphoma (DLBCL) are old (>65 years of age) and a simplified geriatric assessment is essential to choose the correct treatment intensity. Fit older patients can benefit from standard immunochemotherapy, while unfit/frail patients may require reduced doses or less toxic agents.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Rong Shen, Di Fu, Lei Dong, Mu-Chen Zhang, Qing Shi, Zi-Yang Shi, Shu Cheng, Li Wang, Peng-Peng Xu, Wei-Li Zhao
Summary: Genetic classification is essential for identifying genetic subtypes of DLBCL and guiding targeted therapy. The LymphPlex algorithm, based on mutations and rearrangements of specific genes, successfully identified seven distinct subtypes. The genetic subtypes showed different clinical outcomes and biological characteristics, providing potential targets for personalized treatment approaches.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Review
Hematology
Ryan D. Morin, Sarah E. Arthur, Daniel J. Hodson
Summary: The term DLBCL encompasses a diverse collection of tumors, and recent molecular profiling studies have proposed new classification systems to overcome this biological heterogeneity. Challenges include applying these new systems in clinical practice, introducing genomic subtyping and precision medicine into DLBCL, and addressing the implications for current clinical practices and trials.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Lucie Oberic, Frederic Peyrade, Mathieu Puyade, Christophe Bonnet, Peggy Dartigues-Cuilleres, Bettina Fabiani, Philippe Ruminy, Herve Maisonneuve, Julie Abraham, Catherine Thieblemont, Pierre Feugier, Gilles Salles, Fontanet Bijou, Gian-Matteo Pica, Gandhi Damaj, Corinne Haioun, Rene-Olivier Casasnovas, Hassan Farhat, Ronan Le Calloch, Agathe Waultier-Rascalou, Sandra Malak, Jerome Paget, Elodie Gat, Herve Tilly, Fabrice Jardin
Summary: The prognosis of elderly patients with DLBCL is worse than that of young patients. An attenuated dose of chemotherapy and addition of lenalidomide does not significantly improve overall survival compared to standard treatment.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Laura K. Hilton, Henry S. Ngu, Brett Collinge, Kostiantyn Dreval, Susana Ben-Neriah, Christopher K. Rushton, Jasper C. H. Wong, Manuela Cruz, Andrew Roth, Merrill Boyle, Barbara Meissner, Graham W. Slack, Pedro Farinha, Jeffrey W. Craig, Alina S. Gerrie, Ciara L. Freeman, Diego Villa, Judith A. Rodrigo, Kevin Song, Michael Crump, Lois Shepherd, Annette E. Hay, John Kuruvilla, Kerry J. Savage, Robert Kridel, Aly Karsan, Marco A. Marra, Laurie H. Sehn, Christian Steidl, Ryan D. Morin, David W. Scott
Summary: Diffuse large B-cell lymphoma (DLBCL) patients with early disease progression or relapse have poor outcomes. This study found that patients with late relapse had better outcomes after second-line therapy and autologous stem-cell transplantation compared to those with primary refractory or early relapse. Despite concordance in cell-of-origin classification and genetics-based subgroup between diagnostic and relapse biopsies, late relapses showed significant genetic differences and demonstrated branching evolution patterns. In highly divergent tumors, the same genes acquired new mutations independently, suggesting that shared precursor cells constrain tumor evolution towards the same genetics-based subgroups at both diagnosis and relapse.
JOURNAL OF CLINICAL ONCOLOGY
(2023)